Citadel Advisors
TCRX icon

Citadel Advisors’s TScan Therapeutics TCRX Stock Holding History

Citadel Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$322K Buy
318,411
+155,534
+95% +$166K ﹤0.01% 10317
2025
Q4 		$163K Sell
162,877
-227,870
-58% -$330K ﹤0.01% 11220
2025
Q3 		$711K Buy
390,747
+171,760
+78% +$304K ﹤0.01% 8300
2025
Q2 		$318K Buy
218,987
+164,595
+303% +$238K ﹤0.01% 9684
2025
Q1 		$75.1K Sell
54,392
-88,225
-62% -$191K ﹤0.01% 11830
2024
Q4 		$434K Buy
+142,617
New +$646K ﹤0.01% 8877
2024
Q3 		– Sell
-157,963
Closed -$924K – 15235
2024
Q2 		$924K Buy
157,963
+146,531
+1,282% +$1.15M ﹤0.01% 6746
2024
Q1 		$90.8K Buy
+11,432
New +$71.9K ﹤0.01% 11487
2021
Q4 		– Sell
-11,922
Closed -$99K – 14743
2021
Q3 		$99K Buy
+11,922
New +$111K ﹤0.01% 12887

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Citadel Advisors's TCRX Position: Q1 2026 in Review

Citadel Advisors increased its TScan Therapeutics (TCRX) stake by 95% in Q1 2026, buying an estimated $166K and bringing the position to 318,411 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #10317.

Citadel Advisors first reported a position in TCRX in Q3 2021 and has held it in 9 quarters since. The position peaked at $924K in Q2 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Citadel Advisors held 318,411 shares of TScan Therapeutics worth $322K as of Q1 2026.
  • Citadel Advisors bought 155,534 TScan Therapeutics shares in Q1 2026, an estimated $166K.
  • TScan Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10317 holding.
  • Citadel Advisors first reported a position in TScan Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • Citadel Advisors's TScan Therapeutics position peaked at $924K in Q2 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.